Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The continued discovery of therapeutic antibodies, which address unmet medical needs, requires the continued discovery of tractable antibody targets. Multiple protein-level target discovery approaches are available and these can be used in combination to extensively survey relevant cell membranomes. In this study, the MDA-MB-231 cell line was selected for membranome survey as it is a 'triple negative' breast cancer cell line, which represents a cancer subtype that is aggressive and has few treatment options. METHODS: The MDA-MB-231 breast carcinoma cell line was used to explore three membranome target discovery approaches, which were used in parallel to cross-validate the significance of identified antigens. A proteomic approach, which used membrane protein enrichment followed by protein identification by mass spectrometry, was used alongside two phenotypic antibody screening approaches. The first phenotypic screening approach was based on hybridoma technology and the second was based on phage display technology. Antibodies isolated by the phenotypic approaches were tested for cell specificity as well as internalisation and the targets identified were compared to each other as well as those identified by the proteomic approach. An anti-CD73 antibody derived from the phage display-based phenotypic approach was tested for binding to other 'triple negative' breast cancer cell lines and tested for tumour growth inhibitory activity in a MDA-MB-231 xenograft model. RESULTS: All of the approaches identified multiple cell surface markers, including integrins, CD44, EGFR, CD71, galectin-3, CD73 and BCAM, some of which had been previously confirmed as being tractable to antibody therapy. In total, 40 cell surface markers were identified for further study. In addition to cell surface marker identification, the phenotypic antibody screening approaches provided reagent antibodies for target validation studies. This is illustrated using the anti-CD73 antibody, which bound other 'triple negative' breast cancer cell lines and produced significant tumour growth inhibitory activity in a MDA-MB-231 xenograft model. CONCLUSIONS: This study has demonstrated that multiple methods are required to successfully analyse the membranome of a desired cell type. It has also successfully demonstrated that phenotypic antibody screening provides a mechanism for rapidly discovering and evaluating antibody tractable targets, which can significantly accelerate the therapeutic discovery process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Research works printed but not linked: 14
- 10.1038/nrd2241 · DOI · Paper page
- 10.1016/j.bbagen.2005.09.017 · DOI
- 10.1677/erc.1.00766 · DOI
- 10.1073/pnas.0712202105 · DOI
- 10.1007/s10549-010-1293-1 · DOI · Paper page
- 10.1074/jbc.273.21.13047 · DOI · Paper page
- 10.1172/JCI45014 · DOI · Paper page
- 10.1038/bjc.2012.212 · DOI
- 10.1074/jbc.M602547200 · DOI
- 10.1038/bjc.1991.23 · doi:10.1038/bjc.1991.23
- 10.1073/pnas.0908801107 · DOI · Paper page
- 10.1038/nbt0396-309 · DOI · Paper page
- 10.1089/hyb.1997.16.381 · DOI
- 10.1038/256495a0 · DOI · Paper page
Cited by
Lin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Targeting CD73 in the tumor microenvironment with MEDI9447
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208875 · Cited by 287
Self-citation
Metadata
- Authors
- Rust, S., Guillard, S., Sachsenmeier, K., Hay, C., Davidson, M., Karlsson, A., Karlsson, R., Brand, E., Lowne, D., Elvin, J., Flynn, M., Kurosawa, G., Hollingsworth, R., Jermutus, L., & Minter, R.
- Venue
- Molecular Cancer
- Published
- 2013
- Volume
- 12
- Issue
- 1
- Pages
- 11
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2146577096
- Cited by
- 51
- References
- 1
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. https://app.cochat.ai/papers/10.1186/1476-4598-12-11
- The paper
- Rust, S., Guillard, S., Sachsenmeier, K., Hay, C., Davidson, M., Karlsson, A., Karlsson, R., Brand, E., Lowne, D., Elvin, J., Flynn, M., Kurosawa, G., Hollingsworth, R., Jermutus, L., & Minter, R. (2013). Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. Molecular Cancer. https://doi.org/10.1186/1476-4598-12-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.